UNSPSC 51131624: Dabigatran etexilate mesilate

This classification denotes an anticoagulant agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier SC7NUW5IIT. The European Medicines Agency schedules Dabigatran etexilate mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27581. Dabigatran etexilate mesilate generally arises in the molecular formula C34H41N7O5.CH4O3S. The term 'dabigatran etexilate mesilate' is a European Medicines Agency European Public Assessment Report System designation.

SMILES: CCCCCCOC(=O)N=C(C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N.

UNSPSC 51131624 Dabigatran etexilate mesilate is a Commodity code representing a specific anticoagulant pharmaceutical product. State and local governments procure this drug through health and human services departments, corrections agencies, school district health services, and other public health entities for patient care, institutional formularies, and emergency medical supplies. The code encompasses the branded and generic forms of dabigatran etexilate mesilate used in clinical settings where anticoagulation therapy is indicated, typically sourced through pharmaceutical wholesalers, group purchasing organizations (GPOs), or direct manufacturer agreements that state and local buyers leverage via cooperative purchasing frameworks or direct RFP/RFQ processes.

The most recent state and local activity shows a significant mismatch between the code's pharmaceutical scope and actual procurement practice. Sourcewell, a State of Minnesota cooperative purchasing vehicle, posted RFP #061626 on May 12, 2026 with a June 16, 2026 response deadline for Law Enforcement Equipment on behalf of participating county and municipal entities across Washington state and the United States broadly. This opportunity is tagged under the dabigatran etexilate mesilate code but addresses law enforcement supplies and equipment — a category unrelated to pharmaceutical procurement. The source provides no recent opportunities for dabigatran etexilate mesilate itself. State and local pharmaceutical procurements under this code, when they occur, typically flow through established GPO frameworks, state Medicaid channels, or institutional health system cooperative agreements rather than open competitive solicitations, which limits visibility in public notice systems.